Ninmer, Emily K.
Zhu, Hong http://orcid.org/0000-0001-8562-3351
Chianese-Bullock, Kimberly A. http://orcid.org/0000-0001-8676-3671
von Mehren, Margaret http://orcid.org/0000-0001-6158-890X
Haas, Naomi B.
Ross, Merrick I. http://orcid.org/0000-0002-7787-0421
Dengel, Lynn T.
Slingluff, Craig L. Jr http://orcid.org/0000-0002-6664-4373
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA118386, P30 CA044579, P30 CA044579)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 20 November 2023
Accepted: 13 March 2024
First Online: 22 March 2024
Competing interests
: C.L.S. has the following disclosures: Research support to the University of Virginia from Celldex (funding, drug), Glaxo-Smith Kline (funding), Merck (funding, drug), 3 M (drug), Theraclion (device staff support); Funding to the University of Virginia from Polynoma for PI role on the MAVIS Clinical Trial; Funding to the University of Virginia for roles on Scientific Advisory Boards for Immatics and CureVac. Also, C.L.S. has received licensing fee payments through the UVA Licensing and Ventures Group (UVA LVG) for patents for peptides used in these cancer vaccines. Patents relevant to peptides in this vaccine include United States Patent # 6,660,276; 6,558,671; and 7,019,112; however, the terms of those patents have expired. He holds other patents for peptides in melanoma vaccines (US Patent number US 9,345,755 B2, plus one submitted, all managed by UVA LVG. N.B.H. does not have any conflicts relative to melanoma research, but has attended advisory board meetings for Eisai, BMS, Merck, Exelixis in the past 2 years. M.I.R. has relationships with Merck (US Global Advisory Board Member (<$10,000) and Consultant (Travel Expenses) and Amgen (Consultant (travel expenses) and Support to the institution for clinical research support). There are no other disclosures or competing interests for the other authors.